03:40 , Jan 18, 2019 |  BC Innovations  |  Product R&D

Modality moves at Vertex

In licensing a suite of newly discovered gene editing tools, Vertex Pharmaceuticals Inc. is broadening its options for solving problems that its core small molecule technology can’t address. On Jan. 3, Vertex announced a deal...
03:36 , Jan 4, 2019 |  BC Innovations  |  Tools & Techniques

Making AD mice as diverse as patients

The Jackson Laboratory aims to make Alzheimer’s disease mouse models more useful for predicting which patients will respond to therapy by engineering in a high degree of genetic diversity to better reflect trial populations. The...
19:22 , Dec 14, 2018 |  BC Week In Review  |  Company News

Lilly, AC Immune to develop tau inhibitors

Eli Lilly and Co. (NYSE:LLY) partnered with AC Immune S.A. (NASDAQ:ACIU) to develop the biotech's pipeline of tau aggregation inhibitors, dubbed Morphomers, to treat Alzheimer's disease. The deal includes AC Immune's lead candidate, ACI-3024, which...
16:12 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD); frontotemporal dementia; progressive supranuclear palsy (PSP) Patient sample and mouse studies suggest inhibiting LGMN-mediated cleavage of SRPK2 could help treat AD, frontotemporal dementia (FTD) and PSP. In brain tissue samples from...
11:30 , Dec 12, 2018 |  BC Extra  |  Company News

Lilly, AC Immune to develop tau inhibitors

Eli Lilly and Co. (NYSE:LLY) partnered with AC Immune S.A. (NASDAQ:ACIU) to develop the biotech's pipeline of tau aggregation inhibitors, dubbed Morphomers, to treat Alzheimer's disease. The deal includes AC Immune's lead candidate, ACI-3024, which...
03:55 , Dec 7, 2018 |  BC Innovations  |  Tools & Techniques

Filaments line up as MS biomarker

Neurofilament assays appear on track to become the biomarker of choice for a wide range of neurodegeneration studies, given their tight correlation with axon damage and detectability in blood. If prospective trials can reinforce the...
18:51 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting HDAC3 could help treat AD. In a HEK cell line expressing mutant APP, a tool compound HDAC3 inhibitor decreased levels of neurotoxic β amyloid...
17:38 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse models suggest clearing senescent cells could help treat tau-mediated neurodegenerative diseases. In a mouse model of tauopathy expressing mutant human tau in neurons, systemic expression of a fusion human transgene based on...
22:29 , Sep 21, 2018 |  BioCentury  |  Emerging Company Profile

Aprinoia tackles tau

Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates. “We are going to...
18:42 , Sep 19, 2018 |  BC Extra  |  Preclinical News

Mayo Clinic team implicates senescent cells in neurodegenerative diseases

Clearing out senescent brain cells could prevent tau-mediated neurodegeneration and cognitive loss, although it's still too early to determine whether the approach can halt or reverse disease progression, according to a Nature letter from Mayo...